title: Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost.
abstract: OBJECTIVE
  To evaluate the feasibility, efficacy, and cost of outpatient parenteral antimicrobial therapy (OPAT) in the treatment of osteomyelitis.
  
  
  METHODS
  39 patients with an osteomyelitis requiring parenterally administered antibiotics for more than 4 weeks, and able to receive antibiotics at home.
  
  
  METHODS
  All patients had a totally implanted catheter. Antibiotics were administered by continuous infusion using a portable elastomeric infusion system, which was changed every day by the patient or by the home-care nurse. Laboratory monitoring and surveillance were performed weekly. Clinical efficacy, adverse effects and quality of life were recorded.
  
  
  RESULTS
  The most commonly used antibiotics were vancomycin (51%) and beta-lactam (44%) antibiotics. Thirty patients were available for follow-up for a minimum of 12 months after completion of therapy. Twenty-eight (93%) were considered cured of their infection with a mean of 24 +/- 4 months after completion of antibiotic therapy. Adverse effects among the study patients were rare. The 39 patients in our OPAT programme resulted in a potential saving of US $1 873 885 relative to conventional therapy.
  
  
  CONCLUSIONS
  OPAT is practicable and effective and may be the best alternative treatment for patients suffering from osteomyelitis requiring intravenous therapy.
authors.affiliation: Division of Infectious Diseases, Raymond-Poincaré Medical University, Garches, France. louis.bernard@hcuge.ch
authors.forename: L
authors.initials: L
authors.lastname: Bernard
authors.lastname: El-Hajj
authors.forename: B
authors.initials: B
authors.lastname: Pron
authors.forename: A
authors.initials: A
authors.lastname: Lotthé
authors.forename: V
authors.initials: V
authors.lastname: Gleizes
authors.forename: F
authors.initials: F
authors.lastname: Signoret
authors.forename: P
authors.initials: P
authors.lastname: Denormandie
authors.forename: J L
authors.initials: JL
authors.lastname: Gaillard
authors.forename: C
authors.initials: C
authors.lastname: Perronne
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000191:economics* / Q000627:therapeutic use; D002408:Catheters, Indwelling; D016527:Drug Costs; D005260:Female; D019538:Health Care Surveys; D006699:Home Care Services; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010019:Osteomyelitis / Q000188:drug therapy* / Q000191:economics; D010045:Outpatients; D011788:Quality of Life; D012646:Self Administration; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents